1996
DOI: 10.2337/diacare.19.6.580
|View full text |Cite
|
Sign up to set email alerts
|

Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patients

Abstract: Therefore, exogenous GLP-1 is able to lower fasting glycemia also in type I diabetic patients, mainly by reducing glucagon concentrations. However, this alone is not sufficient to normalize fasting plasma glucose concentrations, as was previously observed in type II diabetic patients, in whom insulin secretion (C-peptide response) was stimulated 20-fold.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

6
176
1
10

Year Published

1998
1998
2016
2016

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 315 publications
(193 citation statements)
references
References 16 publications
6
176
1
10
Order By: Relevance
“…It should also be noted that glucagon levels rapidly increased as glucose levels approached the normal range, despite ongoing GLP-1 infusion, suggesting that GLP-1 may improve abnormal alpha cell glucose sensing in type 2 diabetes. The direct suppressive effect of GLP-1 infusion on fasting glucagon levels has further been demonstrated in patients with type 1 diabetes [94] and in patients with advanced type 2 diabetes after 'sulphonylurea failure' [95].…”
Section: Acute Effects Of Exogenous and Endogenous Glp-1 On Alpha Celmentioning
confidence: 93%
“…It should also be noted that glucagon levels rapidly increased as glucose levels approached the normal range, despite ongoing GLP-1 infusion, suggesting that GLP-1 may improve abnormal alpha cell glucose sensing in type 2 diabetes. The direct suppressive effect of GLP-1 infusion on fasting glucagon levels has further been demonstrated in patients with type 1 diabetes [94] and in patients with advanced type 2 diabetes after 'sulphonylurea failure' [95].…”
Section: Acute Effects Of Exogenous and Endogenous Glp-1 On Alpha Celmentioning
confidence: 93%
“…The mechanism whereby GLP-1 inhibits glucagon secretion has been suggested to be indirect relative to its effects on the beta cell (insulin, zinc, glutamate) (58). However, GLP-1 also suppressed glucagon secretion in subjects with type 1 diabetes and no residual beta cell function (59), and recent studies in isolated perfused rat pancreas demonstrated inhibition of glucagon secretion by GLP-1 at glucose levels too low to cause measurable insulin secretion (60) 3) Effects on appetite and food intake. GLP-1 inhibits appetite and food intake in normal subjects(64) as well as in obese subjects with T2DM(65;66), and it is thought that GLP-1 is one of the gastrointestinal hormones that normally regulate food intake(42).…”
Section: Effects On Glucagon Secretionmentioning
confidence: 99%
“…The importance of this with respect to diabetes treatment is perhaps best illustrated in studies of GLP-1 infusion in patients with insulin-requiring diabetes and no residual beta-cell secretory capacity [93]. In these patients, GLP-1 retains substantial glucose lowering activity, in spite of undetectable C-peptide responses, while glucagon secretion is strongly inhibited.…”
Section: Incretin Hormones As Therapeutic Agentsmentioning
confidence: 99%